GlassScriptPhysician profile
Sean Lawless
NPI 1720475122
$8,252.06
in general payments reported to CMS, 2019-2025
36 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,192 · 2021: $813 · 2022: $1,256 · 2023: $1,369 · 2024: $1,210 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,119.75 | 2020-2025 | Perclose Proglide |
| E.R. Squibb & Sons, L.L.C. | $896.58 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $856.96 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $847.58 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.06 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $467.40 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $437.15 | 2022-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $371.71 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $266.89 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $226.77 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.48 | 2020-2023 | Farxiga |
| Novo Nordisk INC | $142.23 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $117.34 | 2021 | |
| Boston Scientific Corporation | $106.86 | 2022-2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $102.92 | 2022-2024 | Opsumit, Uptravi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $74.07 | 2025 | Amvuttra |
| Daiichi Sankyo INC. | $72.12 | 2024-2025 | Injectafer |
| Astellas Pharma US INC | $68.58 | 2020 | |
| Acacia Pharma INC | $56.91 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $52.33 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $27.68 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.00 | 2021-2023 | Seglentis, Livalo |
| Philips North America LLC | $24.37 | 2025 | Mcot |
| Bridgebio Pharma, INC. | $23.06 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $22.76 | 2024 | |
| Endotronix, INC. | $22.32 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Genzyme Corporation | $21.08 | 2025 | |
| Cmp Pharma, INC. | $20.28 | 2022 | |
| Chiesi USA, INC. | $18.92 | 2020 | |
| Amryt Pharma Holdings LTD | $17.74 | 2022 | |
| Lucid Diagnostics INC. | $17.41 | 2022 | |
| Heartflow, INC. | $17.28 | 2022 | |
| Scpharmaceuticals INC. | $16.37 | 2025 | |
| Abiomed | $14.04 | 2024 | Impella |
| Analog Devices INC. | $14.02 | 2024 | Sensinel Cpm Wearable |
| Biotronik INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Lawless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.